|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CHEMOKINES
To understand the regulation of CC chemokine receptor 3 (CCR3)
expression, its gene structure and promoter have been characterized. The CCR3 gene contains 4 exons that give rise to multiple
messenger RNA (mRNA) species by alternative splicing. Exon 1 is present in all transcripts, whereas exon 2 or 3 is present at low frequency (< 10%). Exon 4 contains the open reading frame and 11 bp of the 5'
untranslated region. Northern analysis revealed 4 species of CCR3 mRNA.
Direct sequencing revealed that the first 1 kb of the promoter and exon
1 contained only one mutation in 19 individuals, indicating that the
CCR3 promoter and exon 1 are conserved between individuals. The first
1.6 kb of the 5' flanking region of exon 1 contained promoter elements
including a TATA box and motifs for myeloid transcription factors
and had strong promoter activity in eosinophilic, lymphoid, myeloid,
and respiratory epithelial cell lines. Deletion analysis revealed
differential regulation of the CCR3 promoter in eosinophilic and
epithelial cells suggesting the presence of lineage-specific elements.
Interestingly, exon 1 enhanced the activity of the promoter and this
effect was especially prominent in eosinophilic cells. Thus, the human
CCR3 gene has a complex 5' exon structure, a conserved
promoter with strong activity in multiple cell types, and a functional
5' untranslated exon.
(Blood. 2000;96:2346-2354) The eotaxin receptor, CCR3, is the major chemokine
receptor expressed on eosinophils.1-4 In addition, it is
expressed by other cell types such as basophils and a subpopulation of
Th2 lymphocytes.5-10 Recently, CCR3 has been shown to be
up-regulated on neutrophils and monocytoid U937 cells by interferons in
vitro and to be expressed by endothelial cells, epithelial cells, and mast cells.11-16 The relevance of these findings and the
function of CCR3 on noneosinophils remain to be elucidated because
administration of the CCR3-specific ligand eotaxin in vivo induces only
eosinophil accumulation.17-19 Recent studies in mice
demonstrated CCR3 expression on eosinophils in vivo20 and
polarized Th2 cells in vitro.21 Additionally, mice
deficient in eotaxin have a major impairment in eosinophil
trafficking.22,23 Taken together, these studies imply a
critical role for CCR3 in the orchestration of allergic inflammation.
Because CCR3 is a relatively eosinophil-selective marker, analysis of
the signals that induce its expression may give insight into the
molecular mechanisms for the commitment of myeloid progenitors to the
eosinophil lineage. It is generally believed that specific combinations
of transcription factors determine the lineage fate of hematopoietic
progenitors.24 Although no eosinophil-specific transcription factors have been reported, eosinophil commitment appears
to be regulated by GATA-1, PU-1, and C/EBP proteins.25-29 Consistent with this, DNA binding sites for these transcription factors
are found in several eosinophil-selective promoters, such as the
promoter for major basic protein (MBP), interleukin-5 receptor alpha
(IL-5R To date, the complete messenger RNA (mRNA) and genomic organization of
only a limited number of chemokine receptors has been described (eg,
CXCR1, CXCR2, CCR2, and CCR5).30-33 These studies have
shown that the 5' untranslated region (5'-UTR) can be complex and
contain up to 11 exons as in the CXCR2 gene. As a result, alternative splicing and transcription directed by multiple promoters can give rise to variable mRNA isoforms. The function of these 5'
untranslated exons has not been examined except for a single study
focused on CCR2, demonstrating a transcriptional role for exon 1.33 Furthermore, the promoter can be highly
polymorphic as in the case of CCR5 where a common haplotype, CCR5P1,
confers rapid progression of human immunodeficiency virus
infection.34-37
Taken together, these studies highlight the importance of further
elucidating the gene structure, genetic polymorphisms, and transcriptional regulation of CCR3.
Cell culture and isolation
RNA preparation and Northern blot analysis
5'-Rapid amplification of cDNA ends The template for 5'-rapid amplification of cDNA ends (RACE) was total RNA (1 µg) isolated from human eosinophils and butyric acid/IL-5-differentiated AML14.3D10 cells.39 The Marathon complementary DNA (cDNA) Amplification Kit (Clontech, Palo Alto, CA) was used for 5'-RACE according to the manufacturer's instructions. The sequences of the gene- specific primers were: primary 5'-TCC GGG CTC GAA GGG CAA ACA CA-3' and nested 5'-CCC AAG AGG CCC ACA GTG AAC AC3-'. The 5'-RACE products were subcloned into pCR2.1 and sequenced by the DNA Core Facility, University of Cincinnati.Genomic DNA analysis Human CCR3 genomic clones were isolated by screening a phage P1 library by PCR (DMPC-HFF#1; Genome Systems, St Louis, MO). PCR primers were chosen from the CCR3 ORF sequence and the exon 1 sequence identified by 5'-RACE. The clone identified by the ORF primers (#427-G2)42 and the clone identified by the exon 1 primers (#350-B3) were used for Southern blot analysis and sequencing of the BamHI/HindIII and BglII fragment, respectively.Reporter gene constructs The human CCR3 promoter construct was made as follows: a 1.6-kb sequence proximal to transcription initiation site at position 1544
to +60 of exon 1 was amplified by PCR, cloned into pEGFP-1 (Clontech),
and subcloned into pGL3.basic (Promega, Madison, WI) via the
BglII and BamHI sites. This construct is referred
to as the CCR3-1.6pGL3 construct. The CCR3-1.6pGL3 construct without exon 1 was made by digesting the CCR3-1.6pGL3 construct with
KpnI and ligating the insert into pGL3.basic vector
linearized with KpnI and is referred to as
CCR3-1.6(-exon1)pGL3. The exon 1 construct was engineered by
re-ligating the CCR3-1.6pGL3 construct digested with KpnI
following removal of the insert and is referred to as CCR3-exon1pGL3.
Deletion constructs (referred to as CCR3-0.892pGL3, CCR3-0.257pGL3,
CCR3-0.222pGL3, and CCR3-0.102pGL3) were amplified by PCR,
cloned into pEGFP-1 or pCR2.1, and subcloned into pGL3.basic.
Transient transfection of cell lines and reporter gene expression measurements Hematopoietic cells (AML14.3D10, L1.2, and Jurkat) were transfected by electroporation as previously described26 (with kind guidance from Dr Steven Ackerman, University of Illinois, Chicago, IL). Briefly, 1.5 × 107 cells were electroporated in RPMI with 0.3 to 15 µg plasmid DNA containing the reporter construct and an appropriate amount (5 µg for L1.2 cells and 10 µg for AML and Jurkat) of control construct (pcDNA3. Gal) at 960 µF and 350 V for AML, 300 V for Jurkat, and 250 V for L1.2. Cells
were incubated for 7 hours in RPMI with 10% FCS (10 mL per
electroporation) and lysates were made using 0.25 mL reporter lysis
buffer (Promega) per electroporation. In other experiments, cells were
transfected with Effectene (Qiagen, Valencia, CA) following the
manufacturer's instructions. Promoter activity results were comparable
between experiments performed using the 2 methods. A549 and U937 cells
were transfected using Effectene and lysed 24 hours after transfection.
The pGL3.SV40 (Promega) and the promoterless pGL3.basic vectors were
used as positive and negative controls, respectively. The luciferase
assay was performed per manufacturer's instructions (Promega) using 20 µL of the cell lysate and data were recorded with a Monolight 3010 luminometer (Analytical Luminescence Laboratory, Ann Arbor, MI) as
relative light units (RLU). -Galactosidase activity (from 50 µL
cell lysate) was measured using ONPG (o-nitrophenyl
-D-galacto-pyranoside; Sigma) as a substrate in sodium
phosphate buffer for 2 hours at 37°C. The reaction was stopped by
addition of sodium carbonate and optical density (OD) was measured at
405 nm. All data were normalized by dividing RLU (luciferase assay) by
OD (-galactosidase assay). When the deletion constructs were
compared to wild-type in the AML14.3D10 cell line, transfection
efficiency was normalized by co-transfecting with the renilla
luciferase vector, pRL.SV40 (Promega) and the firefly and renilla
luciferase activities were determined according to manufacturer's
instructions (Dual Luciferase Reporter Assay System; Promega).
Polymorphism detection The human CCR3 promoter and exon 1 were screened for polymorphisms by sequencing 3 overlapping segments amplified by PCR from genomic DNA from 19 individuals (15 with severe allergic asthma and 4 normal controls). The diagnosis of asthma was made based on symptoms and a 12% or greater increase in forced expiratory volume in 1 second (FEV1) after a bronchodilator or after a 2-week trial of oral corticosteroids.43,44 It was classified as severe based on the FEV1 being below 60% and allergic based on a positive skin prick test ( 3 mm wheal with erythema) to
one or more antigens tested (environmental antigens indigenous to the
Ohio valley). Normal controls were nonallergic, nonasthmatic volunteers
with a negative skin prick test to all allergens tested (excluding histamine). Informed consent was obtained from all participants in
these studies. The PCR reactions were performed with approximately 0.3 µg genomic DNA, 0.5 µmol/L each primer, 0.2 mmol/L dNTPs (Roche, Indianapolis, IN), 1.25 U Taq Polymerase (Roche) in a total
volume of 50 µL. Primer pairs were as follows: P1 5'-(TGT
AAA ACG ACG GCC
AGT CCC AAG GGA CAC ATC AGC) and 5'-(CAG
GAA ACA GCT ATG
ACC CCC GGC AAA GGA ATA AAC T); P2 5'-(TGT
AAA ACG ACG GCC
AGT AAC CTT TGC AGC CAC ATT TTG) and 5'-(CAG
GAA ACA GCT ATG
ACC GCT GCT TTA GGG GCT CTC CAC); P3 5'-(TGT
AAA ACG ACG GCC
AGT CCC CCA CCA CTA AAA ATG AGC) and 5'-(CAG
GAA ACA GCT ATG
ACC CCT GGA AAA GCG ACA CCT ACC). All primers had the M13
primer sequence tagged (underlined). PCR products (420-575 bp in
length) were purified (Qiagen PCR Purification Kit) and sequencing was
performed on the ABI sequencer (DNA Core Facility, University of
Cincinnati) using dye-primer chemistry to facilitate detection of
heterozygosity. Data were analyzed using DNA Star software (DNA Star,
Madison, WI).
Northern blot analysis of CCR3 The promoters of chemoattractant receptor genes are often separated from the ORF by one or more large introns. The first evidence that this was the case for CCR3 was derived from analysis of CCR3 mRNA expression. Northern blot analysis using a CCR3 ORF probe revealed multiple hybridizing mRNA bands. The main CCR3 mRNA migrated at ~1.8 kb and 3 weaker species migrated at ~2, ~4, and ~20 kb (Figure 1). The presence of multiple bands may indicate cross-hybridization with related gene products, detection of unspliced heterogeneous nuclear RNA, or the presence of multiple mature CCR3 transcripts that could arise either by alternative splicing or use of different transcription initiation or polyadenylation sites. Therefore, to characterize the CCR3 promoter, we were first interested in determining the complete sequence of the 5'-UTR.
5'-RACE of CCR3 mRNA To characterize the CCR3 promoter, we identified the 5' sequence of the mature mRNA. To accomplish this, we performed 5'-RACE using RNA isolated from eosinophils and butyric acid/IL-5 differentiated AML14.3D10 cells. Products were subsequently subcloned and 12 clones were selected for sequencing by choosing clones with a range of insert sizes. Alignment of the 5'-UTR sequence of 7 clones originally derived from eosinophil RNA revealed a complex organization (Figure 2). All clones had 11 bases upstream from the ATG that were identical to the genomic sequence. Additionally, all clones contained up to 93 bases of the 5'-UTR sequence that is labeled as exon 1 in Figure 2. The truncated forms (with fewer than 93 bases) may arise from premature termination of cDNA synthesis by the reverse transcriptase in vitro or may indicate the presence of multiple transcription start sites in vivo. One 5'-RACE product had 69 bp between the 2 sequences (clone EO12). Another clone had 89 bp between the 2 segments (clone EO9). These data indicate that there are three 5' exons alternatively spliced into the final mRNA. Exon 1 is present in all transcripts, whereas either exon 2 or 3 is present in a small subset of mRNA species. To verify the occurrence of exons 2 and 3, we screened all cloned 5'-RACE products for their expression. Using oligonucleotide probes for each of the exons (EO9: 5'-TCA CTG GCT CCC TCA TTC CG-3' and EO12: 5'-CTG CTG TGG ATT GGA TTA TG3-'), a low frequency of clones (< 10%) containing exons 2 and 3 were identified (data not shown).
Genomic organization of the CCR3 gene To determine the intron/exon structure of the CCR3 gene in more detail, genomic clones containing CCR3 were isolated and characterized. A genomic library was screened using PCR primers specific for the entire CCR3 ORF and exon 1. One of the clones contained the ORF and was used for Southern blot analysis and restriction map analysis. Two overlapping segments (3.8 kb BamHI and 1.7 kb HindIII fragments) were fully sequenced and shown to contain the entire ORF (located on exon 4) as well as 3591 bp of 5' sequence and 445 bp of 3' sequence. Analysis of this sequence revealed that it also contains the 69 additional bases found in 5'-RACE clone EO12, designated exon 3. Another genomic clone was identified by the exon 1 primers, and a 2.9 kb BglII fragment was fully sequenced and found to contain the entire exon 1. Analysis of the intron/exon junctions revealed that they conformed to the splice donor consensus sequence. Southern blotting with the exon 2 sequence (the 89 additional base pairs found in 5'-RACE clone EO9) indicated this exon is located in the ~8 kb BglII- Eco RI segment. To analyze the length of the sequence intervening exons 1 and 3, long-range PCR analysis was performed using primers within the sequenced regions of introns 1 and 2, respectively (Figure 3). This analysis resulted in a specific band of ~17 kb (data not shown). The proposed genomic organization is shown in Figure 3 and the sequence of the 5' BglII fragment is shown in Figure 4.
Analysis of the CCR3 promoter sequences The human CCR3 promoter contained 2 putative TATA-boxes: one from position298 to 294 and the other from position 108 to 103
proximal to the first base of the longest 5'-RACE product. There are
several pyrimidine (CT)-rich segments in the promoter region. For
example, regions from 1361 to 1300 and from 1282 to 1224 have
more than 90% C+T over more than 50 nucleotides (boxed in Figure 4).
Interestingly, it has been reported that CT-rich segments are present
in genes abundantly expressed in myeloid cells, that is, fMLP-receptor
and myeloperoxidase.45,46 The promoter sequence was
analyzed using the publicly available TFSEARCH engine
(http://pdap1.trc.rwcp.or.jp/research/db/TFSEARCH.html) and found to
contain consensus DNA-binding sites for several transcription factors
(ie, GATA-1, AML1, C/EBP, etc). In addition to those shown in Figure 4,
other transcription factor motifs found included AP-1, NF B, Oct-1,
CdxA, CREB, and STAT-x.
The promoter sequence was compared to other chemokine receptor promoter
sequences using BestFit (SeqWeb, Genetics Computer Group, Madison, WI).
Comparison with CCR2 (accession number AF068 265)33 and
CCR5 (accession numbers AF082 742 and AF017 632)31,36 revealed 40% overall identity. However, there were areas of up to 72%
identity between the human CCR3 and CCR2 promoters spanning over 200 bp
(shaded area in Figure 4). Further examination revealed that this
sequence represents an Alu family repeat.47 Comparison to
eosinophil-selective promoters (eg, hCLC, accession number L01 665;
human eosinophil peroxidase (hEPO), accession number M29 904,
hIL-5R Genetic polymorphisms in the CCR3 noncoding sequences Several chemokine receptor promoters have been shown to be highly polymorphic and these polymorphisms are sometimes correlated with disease processes. Hence, we hypothesized that polymorphisms may exist in the 5'-UTR and promoter of CCR3 and that these polymorphisms may have consequences on diseases such as asthma in which CCR3-expressing cells have a major role. We therefore screened genomic DNA from 19 individuals (15 with severe asthma and 4 normal controls) for polymorphisms in the first 1 kb of the promoter sequence and the entire exon 1 using dye-primer sequencing. Surprisingly, we found only one heterozygous polymorphism. DNA from one normal control individual had equal representation of cytosine and thymine bases in position37
(Figure 5 and asterisk on Figure 4),
whereas all other individuals had cytosine in that position. To control
for PCR-introduced mutations, we repeated the same analysis using a
separate PCR-amplified DNA and obtained the same results.
Interestingly, this polymorphism lies in a putative CREB binding site.
This indicates that the CCR3 promoter region and exon 1 are conserved
between individuals.
Characterization of the functional CCR3 promoter To prove that the 5' genomic region has promoter activity, 1.6 kb of 5' DNA containing 60 bp of exon 1 was cloned into a firefly luciferase reporter vector, referred to as CCR3-1.6pGL3. The ability of the promoter construct to promote the expression of the reporter gene was first tested in AML14.3D10 cells, an eosinophilic myelocyte cell line. To correct for differences in transfection efficiency, promoter constructs were co-transfected with pcDNA3.Gal. The eosinophilic
AML14.3D10 cells were transfected either by electroporation as
previously reported (Figure 6A-B) or by a
new method using the Effectene kit (Figure 6C,D). Interestingly,
expression of transfected proteins peaked at different times between
the 2 methods. With electroporation, expression of luciferase was
~30-fold higher 7 hours after the transfection as compared to 24 hours. This kinetic pattern is similar to that reported
previously.26 Conversely, with Effectene expression peaked
at 24 hours (~8-fold higher than at 7 hours, data not shown). When
CCR3 promoter activity was measured at the optimal time point for each
of the methods, strong expression of the luciferase gene was observed
and a dose response was seen with increased DNA concentrations. Of
note, the activity of the CCR3 promoter was comparable to that of the
SV40 promoter used as a positive control. Because of variability
between experiments, 2 representative experiments for each of the
methods are shown in Figure 6. When compared to the basic promoterless
vector, the CCR3 promoter activity was 45-fold higher at 7.5 µg and
130-fold at 15 µg when transfection was performed by electroporation.
For comparison, SV40 promoter activity was 100-fold higher than the basic promoter at 15 µg. When transfection was performed with Effectene, the CCR3 promoter activity was 23- and 120-fold over the
basic vector at 1 and 2 µg, respectively. In the same experiments, SV40 activity was 40-fold above the promoterless vector at 1 µg.
To assess whether the CCR3 promoter is specific for eosinophilic cells
in vitro, we tested the activity of the CCR3 promoter in the L1.2
(mouse B cell), Jurkat (human T cell leukemia), U937 (human
myelomonocytic cells), and A549 (human bronchial epithelial) cell
lines. Activity in those cell lines was above the promoterless vector
and dose dependent (Figure 7). For
instance, in a representative experiment (n = 2-4 for each cell
line), when 1 µg of DNA was transfected using Effectene in the U937
cells the CCR3 promoter activity was 30-fold and the SV40 promoter
activity was 500-fold over the promoterless vector. In the L1.2 cells,
the CCR3 promoter activity was 4-fold and SV40 promoter activity was
37-fold over the promoterless vector. In the Jurkat cells, the CCR3
promoter activity was 13-fold and SV40 promoter activity was 70-fold
over the promoterless vector. In the A549 cells, the CCR3 promoter activity was 56-fold and SV40 promoter activity was 2000-fold over the
promoterless vector.
Deletion analysis of the CCR3 promoter To more precisely localize the regulatory regions of the promoter, a series of deletion mutants were generated and tested for promoter activity (Figure 8). Four deletions of the CCR3-1.6pGL3 construct were prepared in the pGL3 vector. These constructs included the promoter elements starting at positions892,
257, 222, 102 (referred to as CCR3-0.892pGL3, CCR3-0.257pGL3,
CCR3-0.222pGL3, and CCR3-0.102pGL3, respectively). These constructs
were tested for promoter activity by transiently transfecting the A549
cell line. The A549 cells were initially chosen because the
CCR3-1.6pGL3 construct displayed strong promoter activity in this cell
line and transfection efficiency was highest in A549 compared with the
other cell lines (Figure 7D and data not shown). Interestingly, deletion of nucleotides 5' of bp 102 did not diminish promoter activity
compared to the full length vector, CCR3-1.6pGL3 (Figure 8A). Similar
levels of relative promoter activity were seen at 2 lower doses (0.1 and 0.3 µg) of the deletion constructs (data not shown). These data
suggest that the optimal promoter activity is located within the first
102 bp of the region 5' to exon 1.
We were next interested in delineating the role of exon 1 because the function of untranslated exons in chemokine receptor genes has not been extensively examined. Additionally, the finding that exon 1 was conserved between individuals suggested that this exon might have a functional role. To investigate this, we examined the promoter activity of a construct containing full promoter elements without exon 1 (referred to as CCR3-1.6(-exon1)pGL3) and a construct containing exon 1 alone (referred to as CCR3-exon1pGL3). Interestingly, in the absence of exon 1, the promoter activity was reduced by 60% ± 12% (mean ± SD, n = 3) as shown in Figure 8B. Additionally, exon 1 alone exhibited minimal promoter activity. These data indicate that exon 1 enhances the expression of CCR3, but does not act as a promoter element by itself. After establishing the regulatory regions of the CCR3 promoter that
were operational in epithelial cells, we were next interested in
determining if these same regions were involved in eosinophils. We
hypothesized that eosinophilic cells would use distinct promoter regions because CCR3 is relatively eosinophil selective in vivo. To
test this hypothesis, we examined the activity of the critical promoter
constructs identified in respiratory epithelial cells (Figure 8C). We
initially examined the CCR3-0.102pGL3 construct because this region has
full promoter activity in epithelial cells. Interestingly, in
eosinophilic cells, the activity of this construct was reduced by
86.1% ± 11.6% (mean ± SD, n = 3) compared to the full
length construct (CCR3-1.6pGL3). Taken together, these results establish that the major promoter elements in eosinophilic cell are
present 5' of bp
In this study we have demonstrated that the human CCR3 gene has a complex 5' exon structure and a highly conserved promoter with activity in eosinophilic cells. We further report that the CCR3 gene spans ~23 kb and consists of 4 exons. Although exons 1 and 4 are used in all transcripts, exon 2 or 3 is used in only a minority of transcripts. Moreover, the presence of exon 1 enhances the promoter activity of the endogenous promoter, and this effect is especially prominent in eosinophilic cells. Although the full function of the 5' untranslated exons in CCR3 remains to be elucidated, it is interesting to consider that these exons may have regulatory functions. For example, 5'-UTR exons may have a transcriptional role because they can bind transcription factors as is the case for the CCR2 promoter. Using gel mobility shift assays and mutation analysis, it was shown that binding of C/EBP to exon 1 is critical for transcription of CCR2.33 We have obtained evidence for the importance of exon 1 for CCR3 transcription by demonstrating diminished promoter activity when exon 1 is deleted from the promoter construct compared to the CCR3-1.6pGL3 construct (Figure 8). Interestingly, although exon 1 does not contain a C/EBP motif, there are motifs for GATA-1. It still remains possible that the 5' exon may alter the thermodynamic stability of CCR3 mRNA, which has not been examined in the present experiments. Expression of CCR-3 protein may also be regulated at the level of
translation. In previous studies, we have shown that CCR3 is regulated
by post-translational events in eosinophilic cells such as receptor
internalization and degradation.40 The identification of
the complex genomic structure of CCR3 gives further insight into
possible mechanisms of CCR3 regulation. It is interesting to speculate
that the 5'-UTR may regulate CCR3 expression. Factors in the 5'UTR that
promote efficient translation include: (1) the Kozak sequence
immediately surrounding the start codon, (2) the absence of upstream
ATG codons, and (3) short 5'-UTR (most vertebrate mRNAs have a 5'-UTR
of 20-100 nucleotides).50 The Kozak sequence of CCR3 is
relatively weak, with only the purine in position In this report, we have identified strong CCR3 promoter activity in the
eosinophilic AML14.3D10 cell line. In addition, dose-dependent activity
was detected in other myeloid (U937), lymphoid (L1.2 and Jurkat), and
nonhematopoietic (A549) cell lines. This suggests that additional
mechanisms besides transcription may be used to regulate the ultimate
level of CCR3 protein in various cell types because most of these cells
do not express CCR3 constitutively. For instance, the CCR3 promoter may
be active in noneosinophilic cell types, but the
transcribed mRNA may be preferentially spliced to include exon 2 and/or
3 and therefore translation may be inefficient. This in turn may result
in lack of protein production in these cell types. It remains possible
that the activity of the CCR3 promoter in transfected cells may not
accurately reflect the CCR3 promoter activity in vivo. This may be
particularly important for eosinophilic cell lines because these cells
are difficult to transfect compared to other hematopoietic cells.
Additionally, stronger eosinophil selectivity might be observed with
different promoter constructs (eg, longer than 1.6 kb). However, we
have repeatedly observed the activity of the CCR3 promoter to be
comparable or stronger than that of the SV40 promoter in eosinophilic
cells. In contrast, the SV40 promoter activity was always significantly stronger in noneosinophilic cell lines. We cannot, however, rule out
the possibility that this is due to different, cell-specific requirements of the SV40 promoter itself. Several eosinophil-selective gene product promoters have been studied so far. For instance, the
IL-5R To begin addressing the issue of cell-specific elements, we performed
CCR3 promoter deletion construct analysis in respiratory epithelial and
eosinophilic cells (Figure 8). Even though the full length construct
was fully active in a broad array of cells, deletion construct analysis
suggested the presence of eosinophil-specific regulatory elements. For
instance, the promoter construct containing Finally, our studies elucidate the genetic stability of the CCR3 promoter. Several recent reports have described at least 12 single nucleotide polymorphisms (SNP) within the 5' upstream regulatory region of the human CCR5 gene.35-37 Furthermore, a common 10-SNP haplotype, called CCR5P1, has been shown to confer rapid clinical progression of acquired immunodeficiency syndrome. We have previously reported 4 polymorphisms (0.005-0.13 allele frequency) in the ORF of CCR3.41 Taken together, we therefore hypothesized that polymorphisms may exist in the regulatory region of the CCR3 gene. Surprisingly, after analysis of the first 1 kb of CCR3 promoter and exon 1, we found only one individual who had a heterozygous mutation. These results indicate that, in contrast to the coding region, the promoter and exon 1 of CCR3 are conserved between individuals. The conservation of exon 1 supports our results showing an important functional role for this exon. Future studies will need to be conducted to explore the frequency of this polymorphism in the population and any possible correlation with disease phenotypes. In summary, we report that (1) the CCR3 gene has a complex structure containing 4 exons 2 of which are alternatively used in mRNA composition; (2) the CCR3 promoter and exon 1 are conserved between individuals; (3) the 5'-flanking region of exon 1 has strong promoter activity in both hematopoietic and nonhematopoietic cells in vitro; (4) the CCR3 promoter activity is differentially regulated in eosinophilic and respiratory epithelial cells; and (5) the exon 1 is involved in the regulation of CCR3 expression. These studies provide the molecular framework to analyze the regulation of CCR3 transcriptional activation and tissue expression.
The authors wish to thank Drs Jonathan Bernstein and Gurjit Hershey for DNA samples, and Drs Steve Ackerman, Cindy Bachurski, Jeff Whitsett, and Simon Hogan for helpful discussions and critical reading of the manuscript.
Division of Pulmonary Medicine, Allergy and Clinical Immunology, Department of Pediatrics, Children's Hospital Medical Center, Cincinnati, OH; Department of Immunology and Rheumatology, Merck Research Laboratories, Rahway, NJ.
Submitted April 18, 2000; accepted June 5, 2000.
N.Z. is a Parker B. Francis fellow in pulmonary research. This work was supported in part by the AAAAI President's Grant-in-Aid to N.Z.
N.Z. and B.L.D. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Marc E. Rothenberg, Division of Pulmonary Medicine, Allergy and Clinical Immunology, Department of Pediatrics, Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229; e-mail: rothenberg{at}chmcc.org.
1.
Daugherty BL, Siciliano SJ, DeMartino JA, Malkowitz L, Sirotina A, Springer MS.
Cloning, expression, and characterization of the human eosinophil eotaxin receptor.
J Exp Med.
1996;183:2349-2354
2.
Combadiere C, Ahuja SK, Murphy PM.
Cloning and functional expression of a human eosinophil CC chemokine receptor.
J Biol Chem.
1995;270:16491-16494
3.
Combadiere C, Ahuja SK, Murphy PM.
Additions and corrections to cloning and functional expression of a human eosinophil CC chemokine receptor.
J Biol Chem.
1996;271:11034
4.
Ponath PD, Qin S, Post TW, et al.
Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils.
J Exp Med.
1996;183:2437-2448
5.
Sallusto F, Mackay CR, Lanzavecchia A.
Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells.
Science.
1997;277:2005-2007 6. Uguccioni M, Mackay CR, Ochensberger B, et al. High expression of the chemokine receptor CCR3 in human blood basophils: role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest. 1997;100:1137-1143[Medline] [Order article via Infotrieve].
7.
Bonecchi R, Bianchi G, Bordignon PP, et al.
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.
J Exp Med.
1998;187:129-134 8. Gerber BO, Zanni MP, Uguccioni M, et al. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr Biol. 1997;7:836-843[Medline] [Order article via Infotrieve].
9.
Jinquan T, Quan S, Feili G, Larsen CG, Thestrup-Pedersen K.
Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4.
J Immunol.
1999;162:4285-4292
10.
Franz-Bacon K, Dairaghi DJ, Boehme SA, et al.
Human thymocytes express CCR-3 and are activated by eotaxin.
Blood.
1999;93:3233-3240
11.
Bonecchi R, Polentarutti N, Luini W, et al.
Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils.
J Immunol.
1999;162:474-479 12. Lee SC, Brummet ME, Sholl L, et al. Detection of the chemokine receptor CCR3 on endothelial cells and keratinocytes. J Allergy Clin Immunol. 1999;103:S194. 13. Stellato C, Brummet ME, Bickel CA, et al. Characterization of CCR-3 expression on human airway epithelial cells. J Allergy Clin Immunol. 1999;103:S194.
14.
Ochi H, Hirani WM, Yuan Q, et al.
T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro.
J Exp Med.
1999;190:267-280
15.
Romagnani P, De Paulis A, Beltrame C, et al.
Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines.
Am J Pathol.
1999;155:1195-1204
16.
Zella D, Barabitskaja O, Casareto L, et al.
Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells.
J Immunol.
1999;163:3169-3175 17. Rothenberg ME, Ownbey R, Mehlhop PD, et al. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. Mol Med. 1996;2:334-348[Medline] [Order article via Infotrieve]. 18. Ponath PD, Qin SX, Ringler DJ, et al. Cloning of the human eosinophil chemoattractant, eotaxin: expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest. 1996;97:604-612[Medline] [Order article via Infotrieve]. 19. Gonzalo J-A, Jia G-Q, Aquirre V, et al. Mouse eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but is not restricted to a Th2-type response. Immunity. 1996;4:1-14[Medline] [Order article via Infotrieve]. 20. Grimaldi JC, Yu NX, Grunig G, et al. Depletion of eosinophils in mice through the use of antibodies specific for C-C chemokine receptor 3 (CCR3). J Leukoc Biol. 1999;65:846-853[Abstract].
21.
Lloyd CM, Delaney T, Nguyen T, et al.
CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo.
J Exp Med.
2000;191:265-274
22.
Rothenberg ME, MacLean JA, Pearlman E, Luster AD, Leder P.
Targeted disruption of the chemokine eotaxin partially reduces antigen induced tissue eosinophilia.
J Exp Med.
1997;185:785-790
23.
Matthews AN, Friend DS, Zimmermann N, et al.
Eotaxin is required for the baseline level of tissue eosinophils.
Proc Natl Acad Sci U S A.
1998;95:6273-6278
24.
Shivdasani RA, Orkin SH.
The transcriptional control of hematopoiesis.
Blood.
1996;87:4025-4039
25.
Gomolin HI, Yamaguchi Y, Paulpillai AV, et al.
Human eosinophil Charcot-Leyden crystal protein: cloning and characterization of a lysophospholipase gene promoter.
Blood.
1993;82:1868-1874
26.
Yamaguchi Y, Zhang DE, Sun Z, et al.
Functional characterization of the promoter for the gene encoding human eosinophil peroxidase.
J Biol Chem.
1994;269:19410-19419
27.
Kulessa H, Frampton J, Graf T.
GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts.
Genes Dev.
1995;9:1250-1262
28.
Yamaguchi Y, Ackerman SJ, Minegishi N, et al.
Mechanisms of transcription in eosinophils: GATA-1, but not GATA-2, transactivates the promoter of the eosinophil granule major basic protein gene.
Blood.
1998;91:3447-3458 29. McNagny KM, Sieweke MH, Doderlein G, Graf T, Nerlov C. Regulation of eosinophil-specific gene expression by a C/EBP-Ets complex and GATA-1. EMBO J. 1998;17:3669-3680[Medline] [Order article via Infotrieve].
30.
Ahuja SK, Shetty A, Tiffany HL, Murphy PM.
Comparison of the genomic organization and promoter function for human interleukin-8 receptors A and B.
J Biol Chem.
1994;269:26381-26389 31. Moriuchi H, Moriuchi M, Fauci AS. Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry. J Immunol. 1997;159:5441-5449[Abstract].
32.
Guignard F, Combadiere C, Tiffany HL, Murphy PM.
Gene organization and promoter function for CC chemokine receptor 5 (CCR5).
J Immunol.
1998;160:985-992
33.
Yamamoto K, Takeshima H, Hamada K, et al.
Cloning and functional characterization of the 5'-flanking region of the human monocyte chemoattractant protein-1 receptor (CCR2) gene: essential role of 5'-untranslated region in tissue-specific expression.
J Biol Chem.
1999;274:4646-4654
34.
Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK.
The human CC chemokine receptor 5 (CCR5) gene: multiple transcripts with 5'-end heterogeneity, dual promoter usage, and evidence for polymorphisms within the regulatory regions and noncoding exons.
J Biol Chem.
1997;272:30662-30671 35. Mummidi S, Ahuja SS, Gonzalez E, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med. 1998;4:786-793[Medline] [Order article via Infotrieve]. 36. McDermott DH, Zimmerman PA, Guignard F, et al. CCR5 promoter polymorphism and HIV-1 disease progression: Multicenter AIDS Cohort Study (MACS). Lancet. 1998;352:866-870[Medline] [Order article via Infotrieve].
37.
Martin MP, Dean M, Smith MW, et al.
Genetic acceleration of AIDS progression by a promoter variant of CCR5.
Science.
1998;282:1907-1911
38.
Paul CC, Mahrer S, Tolbert M, et al.
Changing the differentiation program of hematopoietic cells: retinoic acid-induced shift of eosinophil-committed cells to neutrophils.
Blood.
1995;86:3737-3744
39.
Zimmermann N, Daugherty BL, Stark JE, Rothenberg ME.
Molecular analysis of CCR-3 events in eosinophilic cells.
J Immunol.
2000;164:1055-1064
40.
Zimmermann N, Conkright JJ, Rothenberg ME.
CC chemokine receptor-3 undergoes prolonged ligand-induced internalization.
J Biol Chem.
1999;274:12611-12618 41. Zimmermann N, Bernstein JA, Rothenberg ME. Polymorphisms in the human CC chemokine receptor-3 gene. Biochim Biophys Acta. 1998;1442:170-176[Medline] [Order article via Infotrieve]. 42. Daugherty BL, Springer MS. The beta-chemokine receptor genes CCR1 (CMKBR1), CCR2 (CMKBR2), and CCR3 (CMKBR3) cluster within 285 kb on human chromosome 3p21. Genomics. 1997;41:294-295[Medline] [Order article via Infotrieve]. 43. American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am Rev Respir Dis. 1991;144:1202-1218[Medline] [Order article via Infotrieve]. 44. Rosa-Rosa L, Zimmermann N, Bernstein JA, Rothenberg ME, Hershey GKK. The R576 interleukin-4 receptor alpha allele correlates with asthma severity. J Allergy Clin Immunol. 1999;104:1008-1014[Medline] [Order article via Infotrieve].
45.
Morishita K, Tsuchiya M, Asano S, Kaziro Y, Nagata S.
Chromosomal gene structure of human myeloperoxidase and regulation of its expression by granulocyte colony-stimulating factor.
J Biol Chem.
1987;262:15208-15213 46. Murphy PM, Tiffany HL, McDermott D, Ahuja SK. Sequence and organization of the human N-formyl peptide receptor-encoding gene. Gene. 1993;133:285-290[Medline] [Order article via Infotrieve]. 47. Weiner AM, Deininger PL, Efstratiadis A. Nonviral retroposons: genes, pseudogenes, and transposable elements generated by the reverse flow of genetic information. Annu Rev Biochem. 1986;55:631-661[Medline] [Order article via Infotrieve].
48.
Sun Z, Yergeau DA, Tuypens T, et al.
Identification and characterization of a functional promoter region in the human eosinophil IL-5 receptor alpha subunit gene.
J Biol Chem.
1995;270:1462-1471 49. Barker RL, Loegering DA, Arakawa KC, Pease LR, Gleich GJ. Cloning and sequence analysis of the human gene encoding eosinophil major basic protein. Gene. 1990;86:285-289[Medline] [Order article via Infotrieve].
50.
Kozak M.
An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.
Nucleic Acids Res.
1987;15:8125-8148
51.
Parola AL, Kobilka BK.
The peptide product of a 5' leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis.
J Biol Chem.
1994;269:4497-4505 52. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5' leader cistron of the human beta 2-adrenergic receptor regulate receptor expression. J Clin Invest. 1998;102:1927-1932[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  D. Miyazaki, T. Nakamura, M. Ohbayashi, C. H. Kuo, N. Komatsu, K. Yakura, T. Tominaga, Y. Inoue, H. Higashi, M. Murata, et al. Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1/CCR3 blockade Int. Immunol., February 1, 2009; 21(2): 187 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. McKimmie, A. R. Fraser, C. Hansell, L. Gutierrez, S. Philipsen, L. Connell, A. Rot, M. Kurowska-Stolarska, P. Carreno, M. Pruenster, et al. Hemopoietic Cell Expression of the Chemokine Decoy Receptor D6 Is Dynamic and Regulated by GATA1 J. Immunol., September 1, 2008; 181(5): 3353 - 3363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Phillips, V. E. L. Stubbs, M. R. Henson, T. J. Williams, J. E. Pease, and I. Sabroe Variations in Eosinophil Chemokine Responses: An Investigation of CCR1 and CCR3 Function, Expression in Atopy, and Identification of a Functional CCR1 Promoter J. Immunol., June 15, 2003; 170(12): 6190 - 6201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Akizawa, C. Nishiyama, M. Hasegawa, K. Maeda, T. Nakahata, K. Okumura, C. Ra, and H. Ogawa Regulation of human Fc{epsilon}RI {beta} chain gene expression by Oct-1 Int. Immunol., May 1, 2003; 15(5): 549 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. DeVries, H. Cao, J. Wang, L. Xu, A. A. Kelvin, L. Ran, L. A. Chau, J. Madrenas, R. A. Hegele, and D. J. Kelvin Genomic Organization and Evolution of the CX3CR1/CCR8 Chemokine Receptor Locus J. Biol. Chem., March 28, 2003; 278(14): 11985 - 11994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, M. P. Soares, Y. Guan, S. Matheravidathu, R. Wnek, K. E. Johnson, A. Meisher, S. A. Iliff, J. S. Mudgett, M. S. Springer, et al. Functional Expression and Characterization of Macaque C-C Chemokine Receptor 3 (CCR3) and Generation of Potent Antagonistic Anti-macaque CCR3 Monoclonal Antibodies J. Biol. Chem., September 6, 2002; 277(37): 33799 - 33810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Huber, A. Denk, R. U. Peter, L. Weber, N. Kraut, and T. Wirth The IKK-2/Ikappa Balpha /NF-kappa B Pathway Plays a Key Role in the Regulation of CCR3 and eotaxin-1 in Fibroblasts. A CRITICAL LINK TO DERMATITIS IN Ikappa Balpha -DEFICIENT MICE J. Biol. Chem., January 4, 2002; 277(2): 1268 - 1275. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) chain, and Charcot-Leyden crystal (CLC) protein.
indicates a gap.
